Human LIF Alexa Fluor® 488-conjugated Antibody

Applications

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Preparation and Storage

Background: LIF

LIF is a 36‑67 kDa highly glycosylated polypeptide (1, 2) produced by a variety of cells including T cells (3), monocytes (4), fibroblasts (5), osteoblasts (6) and mast cells (7). Consistent with its many synonyms, LIF exhibits a broad spectrum of effects on both hematopoietic and nonhematopoietic cells. For example, LIF inhibits the differentiation of embryonic stem cells (8), up regulates the synthesis of acute phase proteins in hepatocytes (9), down regulates lipoprotein lipase activity in adipocytes (10), and preferentially induces a cholinergic phenotype in sympathetic neurons (11). The receptor for LIF (LIF R) has been isolated and found to be a 190 kDa type I transmembrane glycoprotein (12). Although this molecule binds LIF, the resultant LIF-LIF R complex is not sufficient to transduce an intracellular signal. This capability is provided by a 130 kDa signal transducing subunit (gp130) that is common to the functional receptors for IL-6, IL-11, CNTF, and Oncostatin M (13, 14). Since gp130 is a ubiquitously expressed membrane protein, the presence of LIF R (membrane-bound or soluble form) ultimately determines the cell’s responsiveness to LIF. Cells known to express LIF R include osteoblasts (6), hepatocytes (15), macrophages (15), neurons (5), and megakaryocytes (16). Human and mouse LIF exhibit 78% sequence homology, and human LIF is biologically active on mouse cells (17).

Product Datasheets

Related Research Areas

• Cytokines and Receptors in Allergy and Asthma
• Diabetes
• Diabetes and Obesity Research
• IL-6 Family
• Megakaryocytes
• Obesity
• Reproduction
• Search Cytokine and Growth Factor Products